-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson rose 1.7% in early trading on Wednesday, after reports said that the company's Tecvayli and Darzalex reduced the risk of disease progression or death by 83% compared to the standard plan, or supported earlier use; as the treatment paradigm evolved, Carvykti's legendary partner was also receiving attention.

Zhitongcaijing·12/10/2025 15:57:09
Listen to the news
Johnson & Johnson rose 1.7% in early trading on Wednesday, after reports said that the company's Tecvayli and Darzalex reduced the risk of disease progression or death by 83% compared to the standard plan, or supported earlier use; as the treatment paradigm evolved, Carvykti's legendary partner was also receiving attention.